Diligence memo · auto-generated · as of July 2, 2026

Ångström AI

Ångström AI: limited disclosed financing to assess.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Ångström AI operates in Biotech, based in San Francisco, CA, USA. Gen AI molecular simulations that reproduce wetlab results

Sub-sector tags: AI, AI-powered Drug Discovery, Artificial Intelligence, Biotech, Drug discovery, ai/ml, biotech, pharma.

Capital & rounds (filed)filed

Ångström AI has raised — in disclosed capital across 0 recorded rounds, aggregated from public filings.

Valuation (modeled)modeled

No modeled valuation — too little disclosed financing to estimate one.

Financing rhythm & timingmixed

Not enough dated financing history to read a financing rhythm.

Comparablesmixed

Capital scale ranks ahead of 67% of Biotech peers (233 compared).

Modeled value ranks above 67% of those peers.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.